Molecular Diagnosis and Risk Stratification of Sepsis (MARS) Consortium
Research Areas
At a Glance
- Status: Active Consortium
- Year Launched: 2010
- Initiating Organization: Center for Translational Molecular Medicine (CTMM)
- Initiator Type: Government
- Rare disease
- Disease focus:
Sepsis - Location: Europe
Abstract
The Molecular Diagnosis and Risk Stratification of Sepsis (MARS) consortium aims to generate tools that provide rapid and accurate information about an individual patient suffering from sepsis, including which microorganism is responsible for the infection and the severity and stage of the immune response. These tools should be easy to use, be at or close to the patient’s bedside, and provide rapid information to the physician about how to treat each individual patient in the best way.
Mission
The program is organized into the following four Work Packages (WPs):
Consortium History
2010: Consortium started
2013: Data collection completed
2015: Consortium scheduled to complete
Financing
In response to the first call for project proposals in 2007, the Center for Translational Molecular Medicine (CTMM) announced on April 1, 2008, that nine first-call projects would receive research funding amounting to a total of €150 million. On March 10, 2009, it announced that eight new project proposals, submitted in the fall of 2008 in response to the second call for proposals, would receive funding amounting to a total of almost €100 million.
All Dutch university medical centers, plus several universities, a broad spectrum of small and medium-sized enterprises, major industry leaders including Philips and DSM Biomedical Materials, and the Dutch government are involved.
Funding is provided by the Dutch government, industry, and academia. Research is focused firmly on the translational aspects of molecular medicine so that results can be applied as quickly as possible to actual patient care.
MARS is one of the projects from the second call, with a project budget of €14 million, of which 50 percent is contributed by the Dutch government.
|
Other website |
Points of Contact
Principal investigator: Tom van der Poll (Academic Medical Center, Amsterdam)
CTMM program manager: Henny Bruinewoud
Sponsors & Partners
|
Academisch Medisch Centrum (AMC) Amsterdam |
|
BioCartis |
|
Check-Points Health BV |
|
Immunetrics Inc. |
|
Immunexpress |
|
Microbiome Ltd. |
|
Philips Electronics Nederland BV |
|
Universitair Medisch Centrum St Radboud, Nijmegen |
|
Universitair Medisch Centrum Utrecht (UMCU) |